文献速递帕金森病与运动障碍

嵌入式人体闭环脑深部电刺激治疗抽动秽语综合征:一项非随机对照试验

Embedded Human Closed-Loop Deep Brain Stimulation for Tourette Syndrome: A Nonrandomized Controlled Trial.
PubMed 文献 · JAMA Neurol · 2022-01-01

该单中心双盲安全性与可行性试验于2014年2月至2020年6月纳入4例药物难治性抽动秽语综合征患者,评估嵌入式闭环丘脑脑深部电刺激的可行性、安全性和临床疗效。结果显示闭环方法可行且安全,闭环与常规DBS在抽动严重程度评分上无统计学差异,两者均较基线降低。

要点

  • 嵌入式闭环DBS在4例药物难治性抽动秽语综合征患者中可行且安全。
  • 闭环与常规DBS比较,抽动严重程度评分无统计学差异,两者均低于基线。
  • 4例中2例达到YGTSS评分改善至少40%的主要疗效目标。

核心结论

  • 嵌入式闭环脑深部电刺激治疗抽动秽语综合征的抽动症状可行、安全,且结局与常规抽动秽语综合征脑深部电刺激相当。

研究设计与样本

  • 单中心双盲安全性与可行性试验,于2014年2月至2020年6月进行,从佛罗里达大学Norman Fixel研究所筛选并招募6例抽动秽语综合征患者,其中前2例因嵌入式闭环技术尚不可用而被排除,最终分析4例(2男2女;平均[SD]年龄23.7[5.8]岁)。
  • 主要结局在6个月时测量,参与者随访至神经刺激器电池寿命结束;分析日期为2020年8月。
  • 干预为嵌入式闭环刺激系统控制的脑深部电刺激治疗。

主要发现

  • 队列抽动秽语综合征诊断时平均(SD)年龄为8.5(2.9)岁,平均(SD)病程为23.7(5.8)年。
  • 常规DBS的平均(SD)治疗结局为YGTSS改善33.3%(35.7%),Modified Rush Videotape Rating Scale改善52.8%(21.9%)。
  • 4例参与者中2例主要结局变量改善40%,达到主要疗效目标。
  • 采用Wilcoxon符号秩检验比较闭环DBS与常规DBS,抽动严重程度评分无统计学差异,两种方法均显示抽动严重程度评分较基线降低。
  • 研究在全部4例参与者中可行,共报告25例不良事件,其中3例(12%)为研究相关事件;最常见的不良事件为头痛和焦虑。

关键数值与推荐

  • 主要临床结局指标为DBS后6个月时YGTSS评分至少降低40%。
  • 采用Modified Rush Videotape Rating Scale for Tic比较常规DBS与闭环DBS。

临床怎么用

  • 作者认为,嵌入式闭环脑深部电刺激治疗抽动秽语综合征的抽动症状可行、安全,且结局与常规抽动秽语综合征脑深部电刺激相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Because Tourette syndrome (TS) is a paroxysmal disorder, symptomatic relief in individuals with TS may be possible through the application of stimulation only during the manifestation of human tic neural signatures. This technique could be capable of suppressing both motor and vocal tics and would have similar effectiveness to conventional continuous deep brain stimulation (DBS). OBJECTIVE: To evaluate the feasibility, safety, and clinical effectiveness of bilateral centromedian-parafascicular complex thalamic closed-loop DBS as a treatment for medication-refractory TS. DESIGN, SETTING, AND PARTICIPANTS: This single-center double-blinded safety and feasibility trial was conducted between February 2014 and June 2020. Six individuals with TS were screened and recruited from the Norman Fixel Institute at the University of Florida. The primary outcome was measured at 6 months, and participants were followed up for the duration of the neurostimulator battery life. Independent ratings that compared closed-loop and conventional DBS were videotaped. The first 2 of 6 individuals with TS were excluded from the study because the technology for embedded closed-loop capability was not yet available. The date of analysis was August 2020. INTERVENTIONS: DBS therapy controlled by an embedded closed-loop stimulation system. MAIN OUTCOMES AND MEASURES: The primary clinical outcome measure was a minimum of a 40% reduction in the YGTSS score at 6 months following DBS. There was also a comparison of conventional DBS with closed-loop DBS using the Modified Rush Videotape Rating Scale for Tic. RESULTS: The mean (SD) age at TS diagnosis for the cohort was 8.5 (2.9), and the mean (SD) disease duration was 23.7 (5.8) years. Four individuals with TS were analyzed (2 male, 2 female; mean [SD] age, 23.7 [5.8] years). The study showed the closed-loop approach was both feasible and safe. One of the novelties of this study was that a patient-specific closed-loop paradigm was created for each participant. The features and stimulation transition speed were customized based on the signal quality and the tolerance to adverse reactions. The mean (SD) therapeutic outcome with conventional DBS was 33.3% (35.7%) improvement on the YGTSS and 52.8% (21.9%) improvement on the Modified Rush Videotape Rating Scale. Two of 4 participants had a primary outcome variable improvement of 40% meeting the primary efficacy target. When comparing closed-loop DBS with conventional DBS using a Wilcoxon sign-rank test, there was no statistical difference between tic severity score and both approaches revealed a lower tic severity score compared with baseline. The study was feasible in all 4 participants, and there were 25 total reported adverse events with 3 study-related events (12%). The most common adverse events were headache and anxiety. CONCLUSIONS AND RELEVANCE: Embedded closed-loop deep DBS was feasible, safe, and had a comparable outcome to conventional TS DBS for the treatment of tics. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02056873.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Cagle JN, Okun MS, Cernera S, et al. Embedded Human Closed-Loop Deep Brain Stimulation for Tourette Syndrome: A Nonrandomized Controlled Trial. JAMA Neurol. 2022. PMID: 36094652. doi:10.1001/jamaneurol.2022.2741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。